Regulators yank former Lilly drug from market

March 29, 2007
A Parkinson’s disease medication originally developed and sold by Eli Lilly and Co. has been voluntarily pulled from the U.S. market after the Food and Drug Administration reviewed new information that associates it with heart problems.

Pergolide, which Lilly sold under the Permax brand, has been licensed to the Aliso Viejo, Calif., drugmaker Valeant Pharmaceuticals International, according to Bloomberg.

The FDA concluded alternative medications called dopamine agonists are safer. The newer drugs are Mirapex, sold by Boehringer Ingelheim GmbH, and Requip, sold by GlaxoSmithKline Plc.
Source: XMLFULL/XMLFull1046.xml

Recent Articles by IBJ Staff

Comments powered by Disqus